PSMA Antibody CDR Engineering for Targeted Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for targeting prostate-specific membrane antigen (PSMA) in prostate cancer are limited in efficacy and specificity, necessitating the development of more effective and targeted antibody-based treatments.
Innovation Solution
Development of isolated antibodies and antigen-binding portions thereof, specifically designed to bind to PSMA, comprising defined CDR sequences for enhanced binding and therapeutic potential.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies targeting PSMA are used, then treatment is provided, but efficacy and specificity are limited
Solution Approach 1:
The patent applies parameter changes by modifying the antibody structure through defined CDR sequences (SEQ ID NO: 1-6) to improve binding affinity and specificity to PSMA. The engineered antibody variants optimize parameters such as binding strength and target recognition, thereby enhancing therapeutic efficacy while maintaining a focused molecular structure.
Solution Approach 2:
The invention implements local quality by specifically engineering the CDR regions of the antibody to achieve enhanced PSMA binding. The variable regions (VH and VL) are optimized with specific CDR sequences to improve target recognition, while the constant regions maintain standard immunoglobulin functions, creating localized improvements in binding specificity without unnecessary overall complexity.
2Reliability
If current PSMA therapies are used, then treatment is provided, but specificity is limited
Solution Approach 1:
The patent employs parameter changes by optimizing the CDR sequences (SEQ ID NO: 1-6) to enhance binding specificity to PSMA. The engineered antibody variants adjust parameters such as affinity constants and binding kinetics, achieving improved specificity through precise molecular modifications rather than complex multi-component systems.
Solution Approach 2:
The invention applies local quality by focusing optimization on the CDR regions responsible for antigen recognition. The variable domains are engineered with specific CDR sequences to improve PSMA binding specificity, while the constant domains remain unchanged, thereby achieving enhanced specificity through localized structural optimization.
3Reliability
If more effective antibody-based treatments are developed, then therapeutic potential is enhanced, but manufacturing and characterization complexity increases
Solution Approach 1:
The patent utilizes parameter changes by creating antibody variants with optimized CDR sequences that improve therapeutic effectiveness. The engineered antibodies maintain standard immunoglobulin frameworks, allowing production through conventional recombinant DNA technology in mammalian cell lines, thereby balancing enhanced efficacy with manufacturability using established bioprocessing methods.
Data Source
AI summary
The present application provides prostate-specific membrane antigen (PSMA) antibodies such as human monoclonal antibodies against PSMA, nucleic acid molecules encoding the antibodies, expression vectors and host cells used for expression of the antibodies, methods for preparing the same, and their uses such as the treatment of PSMA-related diseases including cancer.